title: Who is the research subject in cluster randomized trials in health research?
abstract: This article is part of a series of papers examining ethical issues in cluster randomized trials (CRTs) in health research. In the introductory paper in this series, we set out six areas of inquiry that must be addressed if the CRT is to be set on a firm ethical foundation. This paper addresses the first of the questions posed, namely, who is the research subject in a CRT in health research? The identification of human research subjects is logically prior to the application of protections as set out in research ethics and regulation. Aspects of CRT design, including the fact that in a single study the units of randomization, experimentation, and observation may differ, complicate the identification of human research subjects. But the proper identification of human research subjects is important if they are to be protected from harm and exploitation, and if research ethics committees are to review CRTs efficiently.We examine the research ethics literature and international regulations to identify the core features of human research subjects, and then unify these features under a single, comprehensive definition of human research subject. We define a human research subject as any person whose interests may be compromised as a result of interventions in a research study. Individuals are only human research subjects in CRTs if: (1) they are directly intervened upon by investigators; (2) they interact with investigators; (3) they are deliberately intervened upon via a manipulation of their environment that may compromise their interests; or (4) their identifiable private information is used to generate data. Individuals who are indirectly affected by CRT study interventions, including patients of healthcare providers participating in knowledge translation CRTs, are not human research subjects unless at least one of these conditions is met.
authors.affiliation: Department of Epidemiology and Biostatistics, University of Western Ontario, London, Canada. andrew.mcrae@albertahealthservices.ca
authors.forename: Andrew D
authors.initials: AD
authors.lastname: McRae
authors.forename: Charles
authors.initials: C
authors.lastname: Weijer
authors.forename: Ariella
authors.initials: A
authors.lastname: Binik
authors.forename: Angela
authors.initials: A
authors.lastname: White
authors.forename: Jeremy M
authors.initials: JM
authors.lastname: Grimshaw
authors.forename: Robert
authors.initials: R
authors.lastname: Boruch
authors.forename: Jamie C
authors.initials: JC
authors.lastname: Brehaut
authors.forename: Allan
authors.initials: A
authors.lastname: Donner
authors.forename: Martin P
authors.initials: MP
authors.lastname: Eccles
authors.forename: Raphael
authors.initials: R
authors.lastname: Saginur
authors.forename: Merrick
authors.initials: M
authors.lastname: Zwarenstein
authors.forename: Monica
authors.initials: M
authors.lastname: Taljaard
mesh_terms: D016000:Cluster Analysis; D003219:Confidentiality; D006302:Health Services Research / Q000941:ethics / Q000331:legislation & jurisprudence / Q000379:methods*; D006801:Humans; D028701:Patient Rights; D018579:Patient Selection / Q000941:ethics; D011369:Professional-Patient Relations; D016032:Randomized Controlled Trials as Topic / Q000941:ethics / Q000331:legislation & jurisprudence / Q000379:methods*; D035842:Research Subjects / Q000145:classification* / Q000331:legislation & jurisprudence; D018570:Risk Assessment; D009626:Terminology as Topic; D016896:Treatment Outcome